Robeco Institutional Asset Management B.V. Purchases 1,158 Shares of STERIS plc $STE

Robeco Institutional Asset Management B.V. grew its position in STERIS plc (NYSE:STE - Free Report) by 26.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,473 shares of the medical equipment provider's stock after purchasing an additional 1,158 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in STERIS were worth $1,315,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of STE. Geneos Wealth Management Inc. boosted its position in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 104 shares during the period. Grove Bank & Trust boosted its position in shares of STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 142 shares during the period. Zions Bancorporation National Association UT bought a new position in shares of STERIS in the first quarter worth approximately $37,000. ORG Wealth Partners LLC bought a new position in shares of STERIS in the first quarter worth approximately $43,000. Finally, Golden State Wealth Management LLC boosted its position in shares of STERIS by 503.0% in the first quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 166 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Insider Buying and Selling at STERIS

In other news, Director Mohsen Sohi sold 4,110 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.96, for a total value of $994,455.60. Following the sale, the director owned 22,361 shares of the company's stock, valued at approximately $5,410,467.56. This represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Karen L. Burton sold 7,900 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the completion of the sale, the chief accounting officer directly owned 5,994 shares in the company, valued at approximately $1,448,929.62. This represents a 56.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,709 shares of company stock worth $4,546,940 over the last three months. 1.07% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on STE shares. Weiss Ratings restated a "buy (b-)" rating on shares of STERIS in a research report on Saturday, September 27th. Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Morgan Stanley upped their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Finally, KeyCorp upped their target price on shares of STERIS from $277.00 to $288.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 22nd. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $273.50.

STERIS Price Performance

STE stock opened at $241.58 on Wednesday. STERIS plc has a 52 week low of $200.98 and a 52 week high of $253.00. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $243.63 and a two-hundred day simple moving average of $235.54. The firm has a market capitalization of $23.79 billion, a P/E ratio of 37.00 and a beta of 1.01.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, beating the consensus estimate of $2.32 by $0.02. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the business earned $2.03 earnings per share. STERIS's quarterly revenue was up 8.8% compared to the same quarter last year. Analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.0%. This is an increase from STERIS's previous quarterly dividend of $0.57. The ex-dividend date was Thursday, September 4th. STERIS's dividend payout ratio (DPR) is 38.59%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.